- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04358848
Follow-Up to the Usability Evaluation of a Portable Oxygen Concentrator
April 21, 2020 updated by: Belluscura LLC
Follow-Up to Human Factors Validation Testing for Use of the Belluscura X-PLO2R™ Portable Oxygen Concentrator System
This study was a follow-up evaluation of modifications made to the instructions in the User Manual following the initial study evaluating how well an individual can put together and use a Portable Oxygen Concentrator (POC).
Study Overview
Detailed Description
The Belluscura X-PLO2R Portable Oxygen Concentrator (POC) is intended for the provision of supplemental oxygen to patients with chronic pulmonary diseases, such as Chronic Obstructive Pulmonary Disease (COPD), and for a patient requiring supplemental oxygen, as prescribed by a physician.
The purpose of this study is to evaluate if the X-PLO2R POC can be used by the intended users without serious errors or problems for the intended use and under the expected use conditions.
Specifically, the study is to evaluate if potential users of the device can correctly, safely and effectively set-up, activate and operate the X-PLO2R POC to receive the required supplemental oxygen; if the intended user can understand and apply the information contained in the Belluscura X-PLO2R Quick Start Guide and User Manual; and to identify any and all use difficulties, problems and errors made during device assembly and operation, and to subsequently mitigate each identified instance of use error through device and/or materials modification, and to subsequently evaluate the effectiveness of each modification.
Study Type
Observational
Enrollment (Actual)
4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Plano, Texas, United States, 75024
- Belluscura LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study population It is patients requiring supplemental oxygen, as prescribed by a physician.
Description
Inclusion Criteria:
- 18 years or older.
- Male or female.
- Suitable for supplemental oxygen use from a suitably qualified and licensed medical professional.
- Voluntarily signed subject consent form.
Exclusion Criteria:
- Company employee.
- Former human factors study participants.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ability to correctly assemble and use the X-PLO2R POC
Time Frame: 2 hours
|
A subject who is able to follow the instructions to correctly assemble and receive oxygen through the X-PLO2R POC will be considered a study pass.A subject who is not able to follow the instructions and does not correctly assemble and receive oxygen through the X-PLO2R POC will be considered a study fail.
|
2 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2020
Primary Completion (Actual)
March 4, 2020
Study Completion (Actual)
March 4, 2020
Study Registration Dates
First Submitted
April 21, 2020
First Submitted That Met QC Criteria
April 21, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
April 24, 2020
Last Update Submitted That Met QC Criteria
April 21, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- BELL_XPLO2R_FU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Supplemental Oxygen
-
Belluscura LLCCompleted
-
Medical University of ViennaCompletedPerioperative | Brain Natriuretic Peptide | Supplemental Oxygen | Cardiac Risk PatientsAustria
-
MemorialCare Health SystemCompletedCesarean Section | Supplemental Oxygen | Umbilical Cord GasesUnited States
-
University of Mary Hardin-BaylorPharmachem InnovationsCompletedEvaluation of Bioavailability of Supplemental Forms of IronUnited States
-
National and Kapodistrian University of AthensRecruitingSurgical Site Infections | Gynecological Cancer | Supplemental OxygenGreece
-
Sakarya UniversityNot yet recruiting
-
University of New HampshireCompletedSupplemental Nutrition Assistance Program Education | Bhutanese Refugee AdultsUnited States
-
Astellas Pharma Global Development, Inc.TerminatedReduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen ExtractionUnited States
-
University of North Carolina, Chapel HillScivation, IncCompleted
-
Medtronic - MITGNot yet recruitingOxygen Saturation
Clinical Trials on X-PLO2R
-
Belluscura LLCCompleted
-
The University of Hong KongLondon School of Hygiene and Tropical Medicine; Nagasaki UniversityCompleted
-
Abbott Medical DevicesRecruiting
-
Catholic University of the Sacred HeartSOFAR S.p.A.UnknownBenign, Premalignant and Malignant Gynecological Disease Confined to the PelvisItaly
-
Azienda Ospedaliera San Giovanni BattistaFondazioneCRTCompletedPneumonia | Osteomyelitis | Fractures | Acute Congestive Heart Failure | Exacerbation of COPDItaly
-
Mansoura UniversityCompletedA 2-year Clinical Impact of Bulk-fill Low-viscosity Resin Composite Liners in Class II Restorations.Dental Caries Class IIEgypt
-
CelltrionCompletedEssential HypertensionSouth Korea
-
On-X Life Technologies, Inc.TerminatedHeart Valve DiseaseUnited States, Puerto Rico, Spain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
The Netherlands Cancer InstituteTerminatedHead and Neck NeoplasmsNetherlands